Altamira Therapeutics Ltd. CYTOF

Altamira Therapeutics Ltd. (CYTOF) announced the publication of a peer-reviewed article highlighting the potential of its RNA nanoparticles to provide disease-modifying treatment for osteoarthritis by targeting cartilage degradation and promoting regeneration. Publication validates RNA nanoparticle platform for osteoarthritis, a major market, potentially boosting investor sentiment and pipeline credibility without guaranteeing clinical success.

Altamira Therapeutics Ltd. (CYTOF) provided a business update and reported full year 2025 financial results. Full-year 2025 financial results and business update influence financial performance and operational outlook.

Altamira Therapeutics Ltd. announced the allowance of a Japanese patent application for its Bentrio nasal spray, which is designed to provide protection against respiratory viruses. This patent will enhance the company's intellectual property portfolio and support its commercialization efforts in Japan, potentially expanding market opportunities for Bentrio. The allowance of the patent is a significant strategic move that could enhance market positioning and investor sentiment.

Altamira Therapeutics Ltd. (CYTOF) announced its participation in the mRNA-Based Therapeutics Summit, where it will present its advancements in mRNA technology and its applications in therapeutics. The summit aims to bring together industry leaders to discuss innovations and developments in mRNA-based treatments, highlighting the growing importance of this technology in the pharmaceutical landscape. Participation in a prominent summit indicates a commitment to innovation and could enhance Altamira's visibility in the mRNA sector.

Altamira Therapeutics Ltd. has received market approval for its Bentrio nasal spray in China, a product designed for the management of allergic rhinitis. This approval marks a significant milestone for the company, expanding its market presence in Asia and potentially increasing revenue streams. The nasal spray is expected to address a growing demand for allergy treatments in the region. Market approval in China represents a significant strategic move that could enhance revenue and market positioning.

Altamira Therapeutics Ltd. announced the certification of its Bentrio Nasal Spray under the Medical Device Regulation, marking a significant regulatory milestone for the product. This certification allows for the commercialization of Bentrio in the European market, aimed at providing relief from nasal symptoms associated with allergies and respiratory infections. The company anticipates that this approval will enhance its market presence and drive future growth. Certification under Medical Device Regulation is a significant regulatory milestone that can enhance market presence and drive growth.

Altamira Therapeutics Ltd. announced the successful delivery of DNA molecules using a novel nanoparticle-based technology. This advancement aims to enhance the effectiveness of gene therapies and could lead to improved treatment options for various diseases. The company is optimistic about the potential applications of this technology in the biopharmaceutical sector. The successful development of nanoparticle-based DNA delivery could significantly enhance Altamira's product offerings and competitive positioning in the biotechnology market.

Altamira Therapeutics Ltd. (CYTOF) provided a business update along with its financial results for the first half of 2025. The company reported significant advancements in its product pipeline and highlighted strategic initiatives aimed at enhancing its market position. Financial results showed a notable increase in revenue, reflecting successful commercialization efforts. Altamira remains focused on innovation and expanding its therapeutic offerings to address unmet medical needs. Significant advancements in the product pipeline and increased revenue indicate a strong potential for future growth and market performance.

Altamira Therapeutics Ltd. announced that the Japan Patent Office Board of Appeals has allowed its patent application for intranasal betahistine dihydrochloride, covering the AM-125 program. This patent adds to existing coverage in over 50 countries, including key markets in North America and Europe. CEO Thomas Meyer expressed optimism about bringing AM-125 to patients suffering from dizziness. Betahistine, an analog of histamine, is approved in about 115 countries for treating vertigo, but its oral form has limited bioavailability. AM-125, an intranasal formulation, offers significantly higher bioavailability and targets acute vestibular syndrome, which affects a large portion of the aging population. Altamira is also developing RNA delivery technologies and holds a stake in Altamira Medica AG, which markets an OTC nasal spray for allergic rhinitis. The patent allowance in Japan significantly enhances the company's competitive position and market potential for AM-125.

Altamira Therapeutics Ltd. has entered a collaboration agreement with an undisclosed company to explore the use of its CycloPhore™ platform for delivering circular RNA payloads. The collaboration will involve in vitro and in vivo testing of CycloPhore nanoparticles, with the partner having the option to negotiate a licensing agreement for the development and commercialization of circRNA nanoparticles. CycloPhore is designed for effective delivery of circRNA, offering advantages such as lower dosing and less frequent administrations compared to linear mRNA. Altamira aims to leverage this partnership to advance RNA drug development. The collaboration could significantly enhance Altamira's product offerings and market position in RNA therapeutics.

Altamira Therapeutics Ltd. (CYTOF) provided a business update and reported its full-year financial results for 2024. The company highlighted key developments in its product pipeline and strategic initiatives aimed at enhancing growth and market presence. Financial results showed a focus on improving operational efficiency and addressing market challenges. Altamira's management expressed optimism about future prospects and ongoing projects, emphasizing their commitment to innovation and shareholder value. The financial results and strategic initiatives indicate a moderately noticeable influence on the company's future performance and market positioning.

Altamira Therapeutics Ltd. will host its Full Year 2024 Financial Results and Business Update Call on April 30, 2025. CEO Thomas Meyer and COO Covadonga Pañeda will present prepared remarks. The call will be in listen-only mode, with a replay available afterward. Altamira focuses on RNA delivery technology and has two siRNA programs in preclinical development, along with a stake in Altamira Medica AG, which markets Bentrio®, an OTC nasal spray for allergic rhinitis. The upcoming financial results and business update may moderately influence investor sentiment and provide insights into the company's strategic direction.

Altamira Therapeutics Ltd. announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent related to Bentrio®, a nasal spray for allergic rhinitis. The patent will protect Bentrio's formulation in the U.S., a key market for OTC allergy products. CEO Thomas Meyer highlighted the significance of this milestone, emphasizing Bentrio's drug-free and preservative-free formulation, which has shown efficacy in clinical trials. The company aims to expand Bentrio's availability, particularly in North America, through partnerships in the consumer health sector. The patent allowance is a significant strategic move that enhances Bentrio's market position and potential revenue in the U.S.

Altamira Therapeutics Ltd. has announced a collaboration focused on radiopharmaceutical targeting strategies. This partnership aims to enhance the development of targeted therapies, potentially improving treatment outcomes in various diseases. The collaboration is expected to leverage Altamira's expertise in drug delivery systems and radiopharmaceuticals, marking a strategic move to expand its portfolio and capabilities in the therapeutic landscape. The collaboration is likely to significantly enhance Altamira's strategic positioning and product offerings in the radiopharmaceutical sector.

Altamira Therapeutics successfully delivered circular RNA using nanoparticles. The successful delivery of circular RNA through nanoparticles could significantly impact Altamira Therapeutics' future product innovation and competitive positioning.

Altamira Therapeutics Ltd. transitions from NASDAQ to OTC Markets under ticker symbol CYTOF due to failure to comply with Nasdaq's minimum bid price rule. Transition to OTCQB may moderately influence Altamira's market performance and competitive positioning.

Altamira Therapeutics Ltd. received a letter from Nasdaq stating non-compliance with minimum bid price rule, intends to appeal. The potential delisting from Nasdaq could have a significant impact on Altamira Therapeutics' future and market performance.

Altamira Therapeutics Ltd. announced extended ISO 13485 certification for Bentrio nasal spray, including production activities, to support growth strategy with strategic contract manufacturer and international distributors. Extended ISO 13485 certification for production activities is a significant move that can impact Altamira Therapeutics Ltd.'s future growth and market performance.

Altamira Therapeutics Ltd. provided a business update and reported its first half 2024 financial results, highlighting progress in RNA delivery technology, expansion with distribution partners for Bentrio®, and evidence of effective mRNA delivery to extrahepatic targets. The article discusses significant advancements in RNA delivery technology and potential collaborations, which could have a significant impact on Altamira Therapeutics Ltd.'s future and market performance.

Altamira Therapeutics Ltd. will host its First Half 2024 Financial Results and Business Update Call on September 24, 2024. The financial results and business update call may moderately influence key areas such as financial performance and competitive positioning.

Altamira Therapeutics closed a public offering of up to $12.0 million, with $4.0 million upfront and potential additional gross proceeds of $8.0 million upon full exercise of warrants. The offering included common shares, pre-funded warrants, and Series A-1 and A-2 common warrants. The public offering and potential additional proceeds are significant strategic moves that could impact Altamira Therapeutics' future financial performance and competitive positioning.

Altamira Therapeutics Ltd. announced pricing of a public offering of up to $12.0 million, with $4 million upfront and potential additional gross proceeds of $8 million upon exercise of warrants. The public offering and potential additional gross proceeds could significantly impact Altamira Therapeutics Ltd.'s future financial position and strategic development.

Altamira Therapeutics expands Bentrio license and distribution agreement with Nuance Pharma to include seven additional countries in East and South East Asia, with a combined population of over 630 million. Expansion of license agreement to include additional countries in a high-population region is a significant strategic move that could impact Altamira Therapeutics' future market performance.

Altamira Therapeutics Ltd. announced that its founder, Chairman, and CEO will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference on September 9-11, 2024. The presentation at the conference may moderately influence Altamira Therapeutics Ltd.'s future performance and market sentiment.

Altamira Therapeutics Ltd. (CYTO) announces significant advancements in immune checkpoint inhibitor therapy, confirms safety of Bentrio nasal spray for athletes, and publishes preclinical data on SOD2 mRNA efficacy in reducing abdominal aortic aneurysm progression. The article describes major strategic moves and significant product developments that could significantly alter Altamira Therapeutics Ltd.'s trajectory and investor sentiment.

Altamira Therapeutics extends distribution agreement for Bentrio to include Sweden and Denmark after successful launch in Norway. Expansion of distribution agreement to additional countries is a significant move that can impact future market performance.

Altamira Therapeutics confirms Bentrio nasal spray is free of prohibited substances for athletes, suitable for use against allergens. Testing showed no presence of over 230 prohibited substances listed by WADA. The confirmation of Bentrio's suitability for athletes and absence of prohibited substances is a significant development that could impact the company's future market performance.

Altamira Therapeutics announced significant enhancement of immune checkpoint inhibition therapy in combination with Zbtb46 mRNA delivered with SemaPhore nanoparticles in animal tumor models, resulting in reduced tumor growth and long-term remission. The combination therapy has the potential to significantly impact Altamira Therapeutics' future by rendering more solid tumor patients responsive to anti-PD1 therapies and improving treatment outcomes.

Altamira Therapeutics successfully treats abdominal aortic aneurysm in animal model using SOD2 mRNA delivered by SemaPhore nanoparticles. The successful treatment of abdominal aortic aneurysm with SOD2 mRNA has the potential to significantly impact Altamira Therapeutics' future product development and market positioning.

Altamira Therapeutics highlights the use of betahistine in managing vertigo, with a focus on residual dizziness in BPPV patients. AM-125, a nasal spray formulation of betahistine, is being developed to improve bioavailability and potentially partner or divest as part of a strategic pivot to RNA delivery technology. The article discusses potential strategic pivot of Altamira Therapeutics towards RNA delivery technology and the development of AM-125, which could significantly impact the company's future direction and market performance.